Healthcare Global Enterprises will host an earnings conference call on Friday, November 6, 2026, at 12:30 pm IST to discuss its unaudited financial results for the quarter and six months ended September 30, 2026.

The company’s Board of Directors is scheduled to meet on Thursday, November 5, 2026, to consider and approve the standalone and consolidated financial statements for Q2FY27 and H1FY27. This announcement follows the initial intimation filed on October 13, 2026, regarding the board meeting date.

Earnings call details

Senior management will present a brief discussion on the Q2FY27 performance before opening the floor for a question-and-answer session with investors and analysts. Participants can join via pre-registration or dial-in numbers provided for domestic and international locations.

Company profile

Headquartered in Bengaluru, Healthcare Global Enterprises operates as India’s largest cancer care provider under the brand HCG. The network comprises 26 hospitals across India and Africa, offering comprehensive cancer diagnosis and treatment services. The company’s registered office is located in Bengaluru, Karnataka.

Healthcare Global Enterprises announced that its step-down subsidiary, Healthcare Global (Kenya) Private Limited (HCG Kenya), has increased its stake in Advanced Molecular Imaging Limited (AMIL) to 50.10%. The transaction was completed on October 5, 2026, converting AMIL from an associate into a subsidiary of HCG Kenya.

HCG Kenya entered into a Share Purchase Agreement with Meditec Systems Limited to acquire 10 ordinary shares of AMIL. The aggregate consideration for this acquisition was KES 42,150, which translates to approximately ₹31,288 as of the transaction date. The payment was made in cash on the same day the agreement was executed.

Transaction details

Prior to this acquisition, HCG Kenya held a 50% stake in AMIL. The purchase of the additional 10 shares increased its holding by approximately 0.10%, bringing the total shareholding to 50.10%. This change in ownership structure means AMIL is no longer classified as an associate but is now a step-down subsidiary of Healthcare Global Enterprises.

The filing confirmed that the transaction does not fall within the ambit of a related party transaction. No specific governmental or regulatory approvals were required for this acquisition.

About Advanced Molecular Imaging Limited

AMIL is incorporated under the laws of Kenya and operates in the healthcare sector, specifically in molecular and diagnostic imaging. The company was incorporated on October 7, 2016.

Financial performance of target

The disclosure provided turnover figures for AMIL for the last three fiscal years ending December 31. The company reported significant revenue generation in FY26 after recording nil turnover in the preceding two years.

What the numbers show

The acquisition cost of KES 42,150 for a 0.10% stake implies a valuation that contrasts sharply with AMIL's reported FY26 revenue of ₹10.96 crore. While the absolute monetary value of the transaction is minimal, the strategic shift from associate to subsidiary status consolidates control within the HCG group structure. The jump from nil revenue in FY24 and FY23 to over ₹10 crore in FY26 indicates recent operational commencement or significant business growth for the Kenyan entity.